TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Maintenance Chemotherapy After Neoadjuvant Chemoradiation Therapy for Distal Rectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* over 18 years old~* tumor potentially resectable en bloc; tumors tethered or fixed to a structure that can be removed~* clinical/radiological stages T2,T3,or T4, N0-1~* ANC \>1500, PLT\>100,000~* AST and alkaline phosphatase \< 2.5 X ULN~* bilirubin \< 1.5 X ULN~* CrCl \> 50 ml/min using Cockcroft-Gault formula~* KPS \>60~* ECOG Performance Scale 0-2~* No malignancies within previous 5 years other than non-melanoma skin cancer, in-situ cervical cancer, in-situ ductal breast cancer~* no evidence of metastatic disease~Exclusion Criteria:~* initial tumor fixation to pelvic bone or side wide; technically unresectable disease~* any evidence of distant metastasis~* perforation~* obstruction~* hereditary non-polyposis colorectal cancer~* synchronous primary colon carcinomas except T1 lesions~* known dihydropyrimidine dehydrogenase deficiency~* prior radiation therapy to the pelvis~* prior chemotherapy for malignancies~* known existing uncontrolled coagulopathy~* pregnancy or lactation~* women of childbearing potential not using reliable and appropriate contraceptive method~* serious, uncontrolled concurrent infection(s)~* participation in any investigational drug study within 4 weeks preceding the start of study treatment~* clinically significant heart disease~* other serious uncontrolled medical conditions that might compromise study participation (in the investigator's opinion)~* major surgery within 4 weeks prior to the study treatment~* lack of physical integrity of the upper GI tract or malabsorption syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 5FU/Leucovorin- post distal rectal srgy (Type: OTHER): Assess complete clinical response rate following neoadjuvant chemoradiation in patients with distal rectal cancer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Stimulation Galvanique Vestibulaire

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* patient with right posterieur parietal lobe lesion~* patient with cerebral vascular stroke~* healthy volonteers Age greater than or equal to 18 written informed consent~Exclusion Criteria:~* patient's refusal to participate to the study~* inability to cooperate~* cognitive trouble~* epilepsy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- patient with right parietal lobe lesion (Type: EXPERIMENTAL): Patient with right parietal lobe lesion
- patient stroke (Type: EXPERIMENTAL): patient with cerebral vascular accident
- healthy volunteers (Type: EXPERIMENTAL): healthy volunteers

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy of Pre-operative Administration of Etoricoxib 120 mg, Etoricoxib 120 mg and Paracetamol 1 g Combination or Placebo in the Treatment of Postoperative Pain in Patients Undergoing Gynaecologic Laparoscopic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Type of gynaecologic surgery:~   * diagnostic laparoscopy~  * sterilization~  * removal of ovarial cyst~  * chromopertubation~  * laparoscopic myomectomy~  * laparoscopic fenestration of ovaria~  * laparoscopic adhesiolysis~2. Age 18-50 years.~3. Evaluated risk of anaesthetic procedure according to ASA (American Society of Anaesthesiologist) classification: ASA I or II.~4. Patients agreed to participate in the study and signed the informed consent.~Exclusion Criteria:~1. ASA III or more~2. Emergency surgery~3. Major laparoscopic surgery i.e. hysterectomy~4. Duration of surgery more than 90 minutes~5. Chronic pain~6. History of hypersensitivity to the active substance or to any of the excipients of study drug (Paracetamol or Etoricoxib)~7. Active peptic ulceration or active gastro-intestinal (GI) bleeding.~8. Patients who have experienced bronchospasm, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria, or allergic-type reactions after taking acetylsalicylic acid or NSAIDs including COX-2 (cyclooxygenase-2) inhibitors.~9. Pregnancy and lactation~10. Severe hepatic dysfunction (serum albumin \< 25 g/l or Child-Pugh score ≥ 10).~11. Estimated renal creatinine clearance \< 30 mL/min.~12. Children and adolescents under 16 years of age.~13. Inflammatory bowel disease.~14. Congestive heart failure (NYHA II-IV).~15. Patients with hypertension whose blood pressure has not been adequately controlled.~16. Established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease, unstable angina.~17. Patient has undergone coronary artery bypass graft surgery, angioplasty, or had myocardial infarction, cerebrovascular accident or transient ischemic attack within the past 6 months.~18. History of drug abuse.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- etoricoxib 120 mg (Type: ACTIVE_COMPARATOR): active control
- 2 (Type: PLACEBO_COMPARATOR): Placebo
- 3 (Type: ACTIVE_COMPARATOR): Paracetamol 1 g and etoricoxib 120 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Abdominal Adipose Tissue Distribution in Type 2 Diabetic Patients Treated During 6 Months With Pioglitazone or Insulin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes~* BMI= 26kg/m2~* Maximal treatment with metformin and sulfonylurea~* HbA1c between 7.5 and 9.5%~Exclusion Criteria:~* Anterior treatment with glitazones~* Anterior treatment with insulin~* Known heart failure~* Hepatopathy~* Renal filtration less than 60ml/min, Hb\<10g/dl~* Corticoids treatment

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): UMULINE NPH at bed time
- 2 (Type: EXPERIMENTAL): pioglitazone 30 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Sterile Versus Clean Gloves Intrapartum and Postpartum Infections at Term

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Between 18 and 50 years old~* Term pregnancy (37w0d to 41w6d gestational age)~* Amniotic membranes were intact on admission~* Patient presenting in spontaneous labor or were to undergo induction of labor~* Patient attempting for a vaginal delivery initially, even if the final delivery method was by cesarean section~Exclusion Criteria:~* Preterm pregnancy (before 37w0d gestational age)~* Postdate pregnancy (after 41w6d gestational age)~* Ruptured membranes or premature rupture of membranes on admission~* Patient being evaluated for preterm labor~* Patient has diagnosis of chorioamnionitis or any intrauterine infection~* Patient has an extrauterine infection that would compromise the diagnosis of intrauterine infection (e.g., COVID, upper respiratory infections, urinary tract infections, cellulitis, appendicitis, etc.)~* Patient experiencing an immunocompromised state (e.g., human immunodeficiency virus, congenital syndromes, transplant recipient, or immunosuppressant use)~* Patient with uncertainty of their gestational age and/or no prenatal care~* Patient with an intrauterine fetal demise~* Patient requesting a termination of the pregnancy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Sterile glove (Type: ACTIVE_COMPARATOR): Sterile glove is usually the standard of care
- Clean glove (Type: EXPERIMENTAL): Clean glove is usually not used or in the event of an emergency or lack of access to sterile gloves in the United States.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Dopamine in Acute Decompensated Heart Failure II

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* patients with New York Heart Association (NYHA) functional class IV heart failure according to the American Heart Association (AHA) classification, namely dyspnea on minimal exertion or rest dyspnea, orthopnea, and paroxysmal nocturnal dyspnea,~* signs of congestion (third heart sound or pulmonary rales on physical examination),~* pulmonary congestion on chest x-ray,~* serum B-type natriuretic peptide levels \> 400 pg/ml or NT-proBNP \> 1500 pg/ml,~* echocardiographic documentation of systolic or diastolic dysfunction,~* age \>18 years old,~* on medical therapy with an ACE-inhibitor and/or a β-blocker,~* experiencing an acute decompensation of known chronic HF,~* baseline oxygen saturation \<90% on admission arterial blood gas~Exclusion Criteria:~* acute de novo HF;~* severe renal failure (serum creatinine \>200 μmol/L or GFR \<30 ml/min/1.73m2)~* admission systolic blood pressure \<90 mm Hg;~* severe valvular disease;~* known adverse reactions to furosemide or dopamine;~* HF secondary to congenital heart disease;~* a scheduled procedure with a need for IV contrast dye;~* a scheduled cardiac surgery within 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- High-dose furosemide (Type: ACTIVE_COMPARATOR): High-dose furosemide (HDF): 20 mg/h continuous IV administration for 8 hours
- Low-dose furosemide (Type: ACTIVE_COMPARATOR): Low-dose furosemide (LDF): continuous IV administration of 5 mg/h furosemide
- Low-dose furosemide combined with low-dose dopamine (Type: ACTIVE_COMPARATOR): Low-dose furosemide combined with low-dose dopamine (LDFD): continuous IV administration of 5 mg/h furosemide combined with 5 μg/kg/min dopamine for a total of 8 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Intensity Modulated Radiation Therapy (IMRT) for Patients With Rectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed adenocarcinoma of the rectum~* T3 or N+ disease by MRI or endoscopic ultrasound. Metastatic disease is permitted, except for known brain metastases, as long as local treatment with RT and surgery is recommended.~* Prior chemotherapy is permitted. For patients who have previously received bevacizumab, the last dose must be greater than 4 weeks prior to initiation of radiation therapy.~* 18 years of age or older~* Life expectancy of greater than 3 months~* ECOG (Eastern Cooperative Oncology Group) Performance Status of 0, 1 or 2~* Normal organ and marrow function as outlined in the protocol~* Women of child-bearing potential and men must agree to use of adequate contraception prior to study entry and for the duration of study participation~Exclusion Criteria:~* Pelvic radiotherapy prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier~* Participants may not be receiving any other investigational agents. Patients may not be receiving any other treatment for their rectal cancer during study participation~* Participants with known brain metastases are excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events~* History of known radiation sensitivity syndrome~* History of inflammatory bowel disease~* Active scleroderma or CREST syndrome~* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements~* Pregnant or nursing women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Short course IMRT (Type: EXPERIMENTAL): Patients will receive short course IMRT (Intensity Modulated Radiation Therapy) prior to surgery. Dose will be 5 Gy x 5, followed by surgery the week after

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Effectiveness of the QuickFix Small Staple

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Subject requires surgery using the Arthrex QuickFix Small Staple for Akin osteotomy.~2. Subject is 18 years of age or older.~3. Subject is not considered a vulnerable subject (i.e. child, pregnant, nursing, prisoner, or ward of the state).~4. Subject signed informed consent and is willing and able to comply with all study requirements.~Exclusion Criteria:~1. Insufficient quantity or quality of bone.~2. Blood supply limitations and previous infections which may retard healing.~3. Foreign-body sensitivity.~4. Any active infection or blood supply limitations.~5. Conditions that tend to limit the patient's ability or willingness to restrict activities or follow directions during the healing period.~6. Subjects that are skeletally immature.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- QuickFix Small Staple (Type: None): The QuickFix Small Staple will be used for an Akin osteotomy to correct hallux valgus interphalangeus.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Percutaneous Tibial Nerve Stimulation (PTNS) Versus PTNS and Fesoterodine Fumarate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female ages \> 18 and \< 100 years old without childbearing potential~* History of overactive bladder~  * with or without urge incontinence)~ * with or without a history of previous anticholinergic use~* At least 8 voids per 24 hours documented by history and physical and voiding diary~Exclusion Criteria:~* Has had PTNS modulation in the past~* Has a primary complaint of stress urinary incontinence~* History of an allergy or sensitivity to tolterodine tartrate tablets or its ingredients~* History of an allergy or sensitivity to fesoterodine tartrate tablets or its ingredients~* Has a recent positive urinalysis for infection~* Has taken anticholinergic medication in the last 4 weeks for overactive bladder~* Has any of the following:~  * pacemakers or implantable defibrillators~ * excessive bleeding~ * urinary or gastric retention~ * nerve damage and/or neuropathy~ * myasthenia gravis, uncontrolled narrow angle glaucoma~ * liver disease or kidney disease~ * QT prolongation.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PTNS + fesoterodine fumarate first, then PTNS + placebo (Type: ACTIVE_COMPARATOR): Participants were to be given Percutaneous Tibial Nerve Stimulation (PTNS) + 4mg of fesoterodine fumarate first for 12 weeks, and followed by 4 weeks of washout followed by 12 weeks of PTNS + placebo.
- PTNS + placebo first, then PTNS + fesoterodine fumarate (Type: PLACEBO_COMPARATOR): Participants were to be given Percutaneous Tibial Nerve Stimulation (PTNS) + placebo for 12 weeks followed by 4 weeks of washout followed by 12 weeks of PTNS + 4mg of fesoterodine fumarate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Respiratory Regulation With Biofeedback in COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 1. Diagnosed COPD, pulmonary spirometry test FEV1/FVC\<70% and FEV1\<80%.~* 2. At least 20 years old and has communicative capacity.~* 3. Can walk by self or assistive device prior hospitalization.~Exclusion Criteria:~* 1. acute exacerbation attack or recurrent acute exacerbation and SpO2\< 90%.~* 2. Can perform respiratory regulation correctly within exercising regularly.~* 3. Know cancer.~* 4. Comorbidity with sever pulmonary and cardiac disease.~* 5. Diseases of musculoskeletal system.~* 6. Psychotic or cognitive disorder that likely not be available to complete study procedures.~* 7. the hearing-impaired or visually disabled.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- experimental (Type: EXPERIMENTAL): The experiment arm will get educational leaflets to pursed-lip with diaphragmatic breathing training and oximetry level evaluation.
- controlled (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Health Economic Trial in Adult Patients Undergoing Open Colectomy MA402S23B301

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, 18 years of age and older.~* Patients scheduled to undergo open segmental colectomy with planned primary anastamosis, as defined by cecectomy, right hemicolectomy, resection of transverse colon, left hemicolectomy, or sigmoidectomy.~* Ability to provide informed consent, adhere to study visit schedule, and complete all study assessments.~Exclusion Criteria:~* Patients with a history of hypersensitivity or idiosyncratic reactions or intolerance to any local anesthetic, opioid, or propofol.~* Patients who abuse alcohol or other drug substance.~* Patients with severe hepatic impairment.~* Patients currently pregnant or who may become pregnant during the course of the study.~* Patients with any psychiatric psychological, or other condition that the Investigator feels may make the patient an inappropriate candidate for this clinical study.~* Patients who have participated in a EXPAREL study within the last 30 days.~* Patients who have received any investigational drug within 30 days prior to study drug administration, or planned administration of another investigational product or procedure during the patient's participation in this study.~In addition, the patient will be ineligible if he or she meets the following criteria during surgery:~* Patients with unplanned multiple segmental resections of large intestine.~* Patients who have unplanned, temporary or permanent colostomies, ileostomies, or the like placed.~* Patients who receive intraoperative administration of opioids (other than fentanyl or analogs) or any other analgesic, local anesthetics, or anti-inflammatory agents.~* Patients who receive Entereg(R).~* Patients who undergo any concurrent surgical procedure during the ileostomy reversal surgery.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Morphine sulfate (Type: ACTIVE_COMPARATOR): morphine sulfate (or Sponsor-approved equivalent)
- EXPAREL (Type: EXPERIMENTAL): EXPAREL (bupivacaine liposome extended-release injectable suspension)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Alopecia Secondary to Endocrine Therapy in Postmenopausal Women With Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal women~* Diagnosed with hormone-receptor positive breast cancer~* Commenced adjuvant endocrine therapy ≥ 3 months ago, specifically Tamoxifen, Anastrozole, Exemestane, and/or Letrozole~* Good command of the English language~* Under the care of a medical oncologist at Princess Margaret Hospital~Exclusion Criteria:~* Previously received chemotherapy~* Recurrent and/or metastatic disease~* History of endocrine, dermatology, or immune system disorders known to alter hair growth (ie. Hypothyroidism and iron deficiency)

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Postmenopausal Women on Endocrine Therapy (Type: None): Postmenopausal women with Breast Cancer that undergo Endocrine Therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues